Osimertinib is a drug that prevents, inhibits or halts the development of a tumour. It is administered as a tablet. If licensed, osimertinib could offer an additional treatment option for patients with advanced NSCLC that is EGFR mutation positive (Ex19del or L858R) in the first line setting.
Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line
Interventions:
Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2017